SCHEMBL6490917

SCHEMBL6490917

Cc1ccc(C(=O)Nc2ccc(OCCc3ccccn3)c([N+](=O)[O-])c2)c(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.47
SMO Q99835 2/20 0.47
MAPT P10636 3/20 0.46
LMNA P02545 3/20 0.46
TDP1 Q9NUW8 1/20 0.43
MTTP P55157 3/20 0.42
APOB P04114 1/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PPARD Q03181 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 2/20 0.39
NR3C1 P04150 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
P2RX1 P51575 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6792614 0.92 SMO (0.55) TRPV1SMOMAPTLMNATDP1
SCHEMBL6492227 0.88 SMO (0.49) TRPV1SMOMTTPAPOBSMN1; SMN2
SCHEMBL6803739 0.87 SMO (0.48) TRPV1SMOMAPTLMNAMTTP
SCHEMBL6504077 0.86 SMO (0.48) TRPV1SMOMTTPAPOBNR3C1
SCHEMBL7084419 0.86 MAPT (0.50) TRPV1SMOMAPTLMNATDP1
SCHEMBL6490835 0.85 SMO (0.50) TRPV1SMOMTTPAPOBNR3C1
SCHEMBL6497088 0.84 HTR2C (0.51) TRPV1SMOMTTPAPOBNPC1
SCHEMBL6804647 0.83 TRPV1 (0.45) TRPV1SMOMTTPAPOBNR3C1
SCHEMBL6804655 0.83 TRPV1 (0.45) TRPV1SMOMTTPAPOBNR3C1
SCHEMBL6488178 0.81 SMO (0.52) TRPV1SMOMTTPAPOBNR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6864268-B2 β3 adrenergic receptor agonists PFIZER INC. (US) 2005-03-08 US disclosed
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 TRPV1 2245/4885SMO 2580/4885MAPT 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.